Register of
Medicinal Products

Product class: Medicinal product with marketing authorization
Medicinal product class: Human medicine
Name of medicinal product: THIOTEPA RIEMSER
Active substances:
Estonian, English, Latin
ATC code: L01AC01
Dosage form: powder for concentrate for solution for infusion
Strength: 15mg
Legal status for supply*: Subject to medicinal prescription
Summary of product characteristics (SPC):
Package information leaflet (PIL): EST
Indication: Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products: - with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients; - when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.
Safety features: Yes
Marketing authorization holder: Esteve Pharmaceuticals GmbH 
Marketing authorization number: EU/1/21/1536 
Marketing authorization issued on: March 26, 2021 
Marketing authorization expires on: March 29, 2026 
Marketing authorization procedure type: Centralised 
Assessment report:   
Package code Name of medicinal product Dosage form Package Legal status Reimbursements Reference price Last imported PƤritolumaa Additional information
1843860  THIOTEPA RIEMSER  powder for concentrate for solution for infusion  15mg 1TK  Prescription      02.04.2024     
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription

You can download Acrobat Reader fromhere